文献速递围术期管理与 ERAS

跨性别患者外源性激素使用与手术风险的系统综述

Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients: A Systematic Review.
PubMed 文献 · JAMA Surg · 2019-01-01

数据有限,但外源性睾酮未发现与静脉血栓栓塞或其他手术并发症风险增加相关,螺内酯有中等证据提示与不良手术结局无关。现有证据不支持术前常规停用所有CSHT。

要点

  • 外源性睾酮未发现增加围术期静脉血栓栓塞或其他并发症风险。
  • 中等证据提示螺内酯与不良手术结局无关。
  • 现有证据不支持术前常规停用全部跨性别激素治疗。

核心结论

  • 当前证据不支持术前常规停用所有CSHT,尤其缺乏停药后恢复用药相关风险的信息。
  • 证据提示无需停用睾酮或螺内酯,但其与围术期结局质量的关联尚未深入研究。
  • 支持术前停用雌激素的证据多基于跨性别患者通常不使用的口服雌激素方案,且即使对这些制剂围术期风险报告也存在矛盾。

研究设计与样本

  • 系统综述,在PubMed和Excerpta Medica Database进行系列检索。
  • 检索词包括睾酮、雌激素、雌二醇、口服避孕药、螺内酯、醋酸环丙孕酮、非那雄胺、度他雄胺、亮丙瑞林、戈舍瑞林、组氨瑞林,并与手术、围术期、血栓形成、血栓栓塞、手术等词组合。
  • 检索未限于跨性别人群的围术期结局,因为许多外科医生常规术前停用激素使该研究无法进行。
  • 排除动物研究、病例报告、未明确讨论手术结局及仅限于切除激素敏感组织的研究。

主要发现

  • 数据有限,但外源性睾酮未发现与静脉血栓栓塞或其他手术并发症风险增加相关。
  • 中等证据提示螺内酯与不良手术结局无关。
  • 雌激素使用与围术期血栓形成的数据不一致,且未涉及最常用于CSHT的雌激素类型。

关键数值与推荐

  • 其中1篇关于CSHT,12篇关于雌激素和孕激素,1篇关于睾酮,4篇关于螺内酯和抗雄激素。
  • 中等证据提示螺内酯与不良手术结局无关。

临床怎么用

  • 对使用睾酮或螺内酯的跨性别患者,现有证据提示无需术前停药。
  • 对使用雌激素者,支持术前停药的主要证据基于跨性别患者少用的口服方案,应个体化评估。
  • 需进一步研究明确继续激素治疗的安全性及短期停药的风险。

局限性

  • 数据有限,部分药物证据仅为中等强度。
  • 雌激素与围术期血栓形成的证据不一致,且未涉及CSHT常用雌激素类型。
  • 缺乏停药后恢复用药相关风险的信息。
  • 因常规术前停药,难以在跨性别人群中直接研究激素对结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A growing number of transgender patients are receiving gender-affirming hormone treatments. It is unclear whether the evidence supports the current practice of routinely discontinuing these hormones prior to surgery. OBJECTIVE: To determine how medications used in cross-sex hormone treatment (CSHT) affect perioperative risk. EVIDENCE REVIEW: A series of searches were carried out in PubMed and Excerpta Medica Database to identify articles using each of the terms testosterone, estrogen, estradiol, oral contraceptive, spironolactone, cyproterone acetate, finasteride, dutasteride, leuprolide, goserelin, and histrelin, in combination with the terms surgery, perioperative, thrombosis, thromboembolism, and operative. The search was not restricted to perioperative outcomes in transgender populations because many surgeons routinely discontinue hormone use prior to surgery in this population, which makes it impossible to study how hormones affect outcomes. Additional sources were also identified from the texts of reviewed articles. Articles were excluded if they were animal studies or case reports, did not explicitly discuss surgical outcomes, or were restricted to removal of hormonally sensitive tissues. FINDINGS: Eighteen articles addressing perioperative outcomes were identified by this systematic review, including 1 on CSHT, 12 on estrogens and progesterones, 1 on testosterone, and 4 on spironolactone and antiandrogens. Data were limited, but use of exogenous testosterone was not found to be associated with an increased risk of venous thromboembolism or other complications during surgery. Moderate evidence suggests that spironolactone is not associated with negative surgical outcomes. The data linking estrogen use and thrombosis is inconsistent in the perioperative period and does not address the types of estrogens most often used for CSHT. CONCLUSIONS AND RELEVANCE: Current evidence does not support routine discontinuation of all CSHT prior to surgery, particularly given the lack of information on risks associated with resuming these medications after they have been stopped. Evidence suggests there is no need to discontinue either testosterone or spironolactone, although their association with perioperative outcome quality has not been studied in depth. Most of the evidence that supports discontinuation of estrogen prior to surgery is based on oral estrogen regimens that are not typically used in transgender patients, and even with those formulations, there are conflicting reports on perioperative risk. Further research is needed to determine the safety of continuing hormone treatment and elucidate risks of short-term discontinuation.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Boskey ER, Taghinia AH, Ganor O, et al. Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients: A Systematic Review. JAMA Surg. 2019. PMID: 30516808. doi:10.1001/jamasurg.2018.4598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。